IRLAB Therapeutics (OMX: IRLABA)

Currency in SEK

Last close As at 09/06/2023


0.48 (5.70%)

Market capitalisation


Based in Sweden, IRLAB Therapeutics is focused on developing novel drugs for the treatment of neurodegenerative diseases utilising its ISP technology platform. Its two lead assets, mesdopetam and pirepemat, are in late-stage clinical trials for the symptomatic treatment of Parkinson’s disease (PD).

PD is characterised by a triad of cardinal motor symptoms, although non-motor symptoms are as debilitating and remain undertreated. Despite substantial efforts to develop disease-modifying approaches in PD, symptomatic treatment remains the mainstay.

IRLAB Therapeutics_resized



Equity Analyst

Soo Romanoff

Soo Romanoff

Managing Director - Head of Content, Healthcare

Key Management

  • Viktor Siewertz


Balance Sheet

Forecast net cash (SEKm)


Forecast gearing ratio (%)


Share Price Performance

Price Performance
% 1M 3M 12M
Actual (4.7) (10.3) (76.3)
Relative (5.5) (10.3) (76.9)
52 week high/low SEK41.8/SEK7.5


IRLAB Therapeutics is focused on developing novel, potential first-in-class treatments for the symptoms of PD and other central nervous system (CNS) disorders. Its proprietary ISP discovery platform has been validated by the progress of its two lead assets, pirepemat and mesdopetam, which have novel mechanisms of action. Pirepemat is an oral prefrontal cortex enhancer in a Phase IIb trial for the treatment of impaired balance and falls in PD. Mesdopetam, an oral D3 antagonist, failed to hit primary endpoints in a Phase IIb trial for levodopa-induced dyskinesias in January 2023; however, the study did meet a key secondary efficacy endpoint. IRLAB has licensed the global rights for mesdopetam to Ipsen and we await further communication on how this data will define Ipsen’s future development strategy for the drug. IRLAB is also developing three preclinical assets, IRL942, IRL757 and IRL117 for various CNS indications. The company remains well funded in the medium term.

Y/E Dec Revenue (SEKm) EBITDA (SEKm) PBT (SEKm) EPS (öre) P/E (x) P/CF (x)
2021A 207.9 56.1 91.1 176.0 5.1 8.8
2022A 61.3 (108.3) (113.1) (218.0) N/A N/A
2023E 0.2 (205.1) (208.4) (402.0) N/A N/A
2024E 0.2 (187.0) (190.2) (367.0) N/A N/A

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free